Outlook Therapeutics (OTLK) Equity Average (2016 - 2026)

Outlook Therapeutics (OTLK) has 11 years of Equity Average data on file, last reported at -$33.8 million in Q1 2026.

• Equity Average for Q1 2026 came in at -$33.8 million, up 18.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$33.8 million (up 18.38% YoY), and the FY2025 annual result was -$52.6 million, down 20.28% from the prior year.
• Equity Average rose to -$33.8 million in Q1 2026 per OTLK's latest filing, from -$35.4 million in the prior quarter.
• Over five years, Equity Average peaked at $42.4 million in Q1 2022 and troughed at -$109.0 million in Q2 2024.
• A 5-year average of -$25.0 million and a median of -$33.8 million in 2026 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average surged 733.18% in 2022, then plunged 4471.4% in 2024.
• A 5-year view of Equity Average shows it stood at $12.2 million in 2022, then slumped by 258.32% to -$19.4 million in 2023, then sank by 218.11% to -$61.7 million in 2024, then surged by 42.66% to -$35.4 million in 2025, then rose by 4.51% to -$33.8 million in 2026.
• Business Quant data shows OTLK's Equity Average at -$33.8 million in Q1 2026, -$35.4 million in Q4 2025, and -$34.7 million in Q3 2025.